237 related articles for article (PubMed ID: 23744509)
21. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B;
Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
[TBL] [Abstract][Full Text] [Related]
22. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age.
Haas H; Richard P; Eymin C; Fiquet A; Kuter B; Soubeyrand B
Hum Vaccin Immunother; 2019; 15(4):778-785. PubMed ID: 30481110
[TBL] [Abstract][Full Text] [Related]
24. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
Nolan T; McIntyre P; Roberton D; Descamps D
Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
[TBL] [Abstract][Full Text] [Related]
25. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children.
Guerra FA; Gress J; Werzberger A; Reisinger K; Walter E; Lakkis H; Grosso AD; Welebob C; Kuter BJ;
Pediatr Infect Dis J; 2006 Oct; 25(10):912-9. PubMed ID: 17006287
[TBL] [Abstract][Full Text] [Related]
26. Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured with recombinant human albumin.
Rüger G; Gabutti G; Rümke H; Rombo L; Bernaola E; Diez-Domingo J; Martinon-Torres F; Høgh B; Konstantopoulos A; Fiquet A; Thomas S; Eymin C; Baudin M
Pediatr Infect Dis J; 2012 Nov; 31(11):1166-72. PubMed ID: 22772170
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age.
Miller E; Andrews N; Waight P; Findlow H; Ashton L; England A; Stanford E; Matheson M; Southern J; Sheasby E; Goldblatt D; Borrow R
Clin Vaccine Immunol; 2011 Mar; 18(3):367-72. PubMed ID: 21191076
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group.
Reuman PD; Sawyer MH; Kuter BJ; Matthews H
Pediatr Infect Dis J; 1997 Jul; 16(7):662-7. PubMed ID: 9239770
[TBL] [Abstract][Full Text] [Related]
30. Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers.
Korbal P; Wysocki J; Jackowska T; Kline M; Tamimi N; Drozd J; Lei L; Peng Y; Giardina PC; Gruber W; Scott D; Watson W
Pediatr Infect Dis J; 2024 Jun; 43(6):587-595. PubMed ID: 38456705
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
32. A combination vaccine against measles, mumps, rubella and varicella.
Knuf M; Faber J; Barth I; Habermehl P
Drugs Today (Barc); 2008 Apr; 44(4):279-92. PubMed ID: 18536786
[TBL] [Abstract][Full Text] [Related]
33. Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.
Prymula R; Povey M; Brzostek J; Cabrnochova H; Chlibek R; Czajka H; Leviniene G; Man S; Neamtu M; Pazdiora P; Plesca D; Ruzkova R; Stefkovicova M; Usonis V; Verdanova D; Wysocki J; Casabona G; Habib MA
Vaccine; 2021 May; 39(19):2643-2651. PubMed ID: 33858718
[TBL] [Abstract][Full Text] [Related]
34. Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX.
Shinefield HR; Black SB; Staehle BO; Adelman T; Ensor K; Ngai A; White CJ; Bird SR; Matthews H; Kuter BJ
Pediatr Infect Dis J; 1998 Nov; 17(11):980-5. PubMed ID: 9849978
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers.
Klein NP; Shepard J; Bedell L; Odrljin T; Dull P
Vaccine; 2012 Jun; 30(26):3929-36. PubMed ID: 22504039
[TBL] [Abstract][Full Text] [Related]
36. Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity.
Hesley TM; Reisinger KS; Sullivan BJ; Jensen EH; Stasiorowski S; Meechan C; Chan CY; West DJ;
Pediatr Infect Dis J; 2004 Mar; 23(3):240-5. PubMed ID: 15014300
[TBL] [Abstract][Full Text] [Related]
37. Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months.
Mufson MA; Diaz C; Leonardi M; Harrison CJ; Grogg S; Carbayo A; Carlo-Torres S; JeanFreau R; Quintero-Del-Rio A; Bautista G; Povey M; Da Costa C; Nicholson O; Innis BL
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):339-48. PubMed ID: 26582873
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial.
Gillet Y; Habermehl P; Thomas S; Eymin C; Fiquet A
BMC Med; 2009 Apr; 7():16. PubMed ID: 19366435
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age.
Rinderknecht S; Michaels MG; Blatter M; Gaglani M; Andrews W; Abughali N; Chandreshekaran V; Trofa AF
Pediatr Infect Dis J; 2011 Oct; 30(10):e179-85. PubMed ID: 21617573
[TBL] [Abstract][Full Text] [Related]
40. A postmarket safety comparison of 2 vaccination strategies for measles, mumps, rubella and varicella in Italy.
Cocchio S; Zanoni G; Opri R; Russo F; Baldo V;
Hum Vaccin Immunother; 2016 Mar; 12(3):651-4. PubMed ID: 26528829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
